Melior Is Recognized as CRO of the Year by Life Sciences Review
EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. (Melior) announced today that it has been selected as a top-20 CRO in the most recent edition of Pharma Tech Outlook magazine. This cover story article recognized Melior’s approach towards providing bespoke solutions in the preclinical in vivo pharmacology space and its pioneering achievements in phenotypic screening vis-à-vis its theraTRACE® platform.
EXTON, Pa.--(BUSINESS WIRE)--Melior Discovery, Inc. (Melior) announced today significant additions to its management organization. Joining the Melior organization will be Dr. Ken Kilgore (PhD, MBA) as Vice President of Pharmacology. Also joining Melior will be Dr. Hongyan Li as Director of Oncology. In addition, Melior veteran, Dr. Vivian Cong, will rise to the role of Vice President of Research and Development.
EXTON, Pa.--(BUSINESS WIRE)-- Melior Pharmaceuticals (Melior) has been awarded a grant from the Commonwealth of Pennsylvania’s COVID-19 Vaccines, Treatments and Therapies (CV-VTT) Program, which is designed to support rapid advancement of promising COVID-19 therapies. The planned study is intended to recruit 428 subjects who were recently diagnosed with COVID-19, have early symptoms, but are not hospitalized. Tolimidone is expected to significantly mitigate the number of COVID-19 subjects who develop respiratory distress and the severity of respiratory distress if that should occur. Tolimidone will be taken as an orally administered pill once a day.